Thailand

**Population 2018**: 69 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>106 (81–136)</td>
<td>153 (116–195)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>11 (8.2–14)</td>
<td>15 (12–20)</td>
</tr>
<tr>
<td>MDR-RR-TB incidence**</td>
<td>4 (2.3–6.1)</td>
<td>5.7 (3.3–6.8)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>8.2 (6.9–12)</td>
<td>13 (9.9–17)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>2.3 (1.7–3)</td>
<td>3.3 (2.4–4.4)</td>
</tr>
</tbody>
</table>

**Estimated proportion of TB cases with MDR/RR-TB, 2018**
- % tested with rapid diagnostics at time of diagnosis: 19%
- % with known HIV status: 79%
- % pulmonary: 85%
- % bacteriologically confirmed***: 59%
- % children aged 0-14 years: 1%
- % women: 31%
- % men: 68%

**Total cases notified**: 86 949

**Universal health coverage and social protection**
- % tested with rapid diagnostics at time of diagnosis: 19%
- % with known HIV status: 79%
- % pulmonary: 85%
- % bacteriologically confirmed***: 59%
- % children aged 0-14 years: 1%
- % women: 31%
- % men: 68%

**Universal health coverage and social protection**
- Tested with rapid diagnostics at time of diagnosis: 19%
- With known HIV status: 79%
- Pulmonary: 85%
- Bacteriologically confirmed***: 59%
- Children aged 0-14 years: 1%
- Women: 31%
- Men: 68%

**Drug-resistant TB care, 2018**
- % of bacteriologically confirmed TB cases tested for rifampicin resistance***: 30%
  - New cases: 30%
  - Previously treated cases: 62%

**Laboratory-confirmed cases**
- MDR/RR-TB: 1312, XDR-TB: 29
- Patients started on treatment**: 665

**Treatment success rate and cohort size**
- New and relapse cases registered in 2017: 84% (80 160)
- Previously treated cases, excluding relapse, registered in 2017: 55% (1 848)
- HIV-positive TB cases registered in 2017: 73% (7 130)
- MDR-RR-TB cases started on second-line treatment in 2016: 61% (952)
- XDR-TB cases started on second-line treatment in 2016: 75% (8)

**TB preventive treatment, 2018**
- % of HIV-positive people (newly enrolled in care) on preventive treatment: 6.4% (5.9–7.1)
- TB cases on preventive treatment:

**TB financing, 2019**
- National TB budget (US$ millions): 27
- Funding source: 88% domestic, 12% international, 0% unfunded

---

* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed